INPROSER Group is confident that the use of biotechnology can make Malaysia an important supplier of high-end sugar in the fast growing international nutraceutical market.
Its president and chief executive officer Henri ten Have said Malaysia had an abundance of raw materials that could be used to produce high-end sugar.
ten Have has signed for a 7-acre piece of land in Bio Valley, Dengkil to start his dream project, In'novase.
The project, costing around RM75mil, would become a large upstream investment to extract high-end sugar for medical use from Orgafeed conversion technology.
The technology involves the use of supercritical fluid chromatography through a simulated moving bed system in the mass production of high-end sugar.
Inproser plans to become a major supplier of high-end natural sugars such as D-Mannose, D-Rhamnose, D-Arabinose, D-Galactose, D-Xylose and a variety of disaccharides.
ten Have said the high-end sugars had potential for downstream products which could bring high added value.
In'novase has entered into an exclusive technical co-operation with Novasep SA of France for the industrial separation and purification process using Orgafeed process technology with an additional bio technological process OZIIG which was also developed and financed by the Inproser group.
The company would continue to develop new technical cooperation with Novasep.
ten Have said high-end sugar available in the market now were mostly created synthetically at molecular level.
As a result, synthetically produced high-end sugars are much more expensive compared with ours which are extracted from their natural state, he said.
According to ten Have, some types of high-end sugars could easily command prices of up to RM1.2mil per tonne, thus bringing in huge foreign exchange earnings for the country.
Besides high-end sugar, the In'novase facility would be able to purify EPA and DHA components at the molecular level from Omega-3 oil obtained from hybrid fishes fed with Omega rich Orgafeed in Inproser farms.
We will conduct advanced research to purify valuable components at molecular level from Vitamin E for special medical applications and development of new medicines, ten Have said.
He also said that the Inproser group had embarked on an extensive programme to transfer biotechnology and allow local graduates to do research for their doctorate studies.
The In'novase project is expected to be operational next year and yield annual revenue of RM500mil within the next three years.
In'novase has only touched the surface of opportunities and we can envision more new nutraceutical applications being developed in our facilities, ten Have said.
Did you find this article insightful?